Evaluation of the use of erythropoietin-stimulating agents in a hospital setting to assess the necessity of a protocol-driven anemia management service
- 27 February 2020
- journal article
- research article
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 33 (2) , 191-194
Abstract
Erythropoietin-stimulating agents (ESA) have revolutionized the management of anemia. However, these agents are not always utilized with proper monitoring parameters, which can present significant safety concerns, unwarranted drug expenditures, and decreased ESA efficacy. This retrospective study assessed the utilization of all ESAs in non–intensive care unit hospitalized patients at a large academic medical center from August 18, 2018, to August 31, 2018, using established guideline-based assessment criteria. Among the 167 doses of ESA evaluated, 86% (n = 144) were utilized in accordance with guideline-based assessment criteria regarding laboratory monitoring of iron studies. However, 24% (n = 40) of ESA doses were administered to patients with active, untreated iron deficiency at the time of administration. Although most ESA doses were utilized in accordance with the guideline-based criteria, interventions can be implemented to further improve anemia treatment. Implementing a protocol-driven anemia management service is one strategy that can improve patient care, advance patient safety, and be cost-beneficial.Keywords
This publication has 8 references indexed in Scilit:
- Erythropoiesis-Stimulating Agent Hyporesponsiveness in End-Stage Renal Disease Patients2015
- Impact of a Clinical Pharmacy Anemia Management Service on Adherence to Monitoring Guidelines, Clinical Outcomes, and Medication UtilizationJournal of Managed Care Pharmacy, 2014
- New models of chronic kidney disease care including pharmacistsCurrent Opinion in Nephrology and Hypertension, 2013
- NoticeKidney International Supplements, 2012
- Pharmacists' interventions in the management of patients with chronic kidney disease: a systematic reviewNephrology Dialysis Transplantation, 2011
- Pharmacist’s role in managing anemia in patients with chronic kidney disease: Potential clinical and economic benefitsAmerican Journal of Health-System Pharmacy, 2007
- Erythropoiesis‐stimulating agent hyporesponsiveness (Review Article)Nephrology, 2007
- Impact of a Pharmacist-Implemented Anemia Management in Outpatients with End-Stage Renal Disease in JapanBiological and Pharmaceutical Bulletin, 2004